EP2020850A4 - NEW CANNABINOIDS AND METHODS OF USE - Google Patents

NEW CANNABINOIDS AND METHODS OF USE

Info

Publication number
EP2020850A4
EP2020850A4 EP07794433A EP07794433A EP2020850A4 EP 2020850 A4 EP2020850 A4 EP 2020850A4 EP 07794433 A EP07794433 A EP 07794433A EP 07794433 A EP07794433 A EP 07794433A EP 2020850 A4 EP2020850 A4 EP 2020850A4
Authority
EP
European Patent Office
Prior art keywords
methods
cannabinoids
new
new cannabinoids
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP07794433A
Other languages
German (de)
French (fr)
Other versions
EP2020850A1 (en
Inventor
Patricia B Williams
Billy R Martin
Frank A Lattanzio
Sandeep Samudre
Raj K Razdan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eastern Virginia Medical School
Original Assignee
Eastern Virginia Medical School
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eastern Virginia Medical School filed Critical Eastern Virginia Medical School
Publication of EP2020850A1 publication Critical patent/EP2020850A1/en
Publication of EP2020850A4 publication Critical patent/EP2020850A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C07D233/61—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms not forming part of a nitro radical, attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/145—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/78—Ring systems having three or more relevant rings
    • C07D311/80—Dibenzopyrans; Hydrogenated dibenzopyrans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyrrole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EP07794433A 2006-05-01 2007-05-01 NEW CANNABINOIDS AND METHODS OF USE Withdrawn EP2020850A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US79614306P 2006-05-01 2006-05-01
PCT/US2007/010474 WO2007130361A1 (en) 2006-05-01 2007-05-01 Novel cannabinoids and methods of use

Publications (2)

Publication Number Publication Date
EP2020850A1 EP2020850A1 (en) 2009-02-11
EP2020850A4 true EP2020850A4 (en) 2010-10-13

Family

ID=38668080

Family Applications (1)

Application Number Title Priority Date Filing Date
EP07794433A Withdrawn EP2020850A4 (en) 2006-05-01 2007-05-01 NEW CANNABINOIDS AND METHODS OF USE

Country Status (6)

Country Link
EP (1) EP2020850A4 (en)
JP (1) JP2009538827A (en)
CN (1) CN101484004A (en)
AU (1) AU2007248760A1 (en)
CA (1) CA2650900A1 (en)
WO (1) WO2007130361A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2341903A1 (en) * 2008-07-31 2011-07-13 Bionorica Research GmbH Cannabinoids for use in treating or preventing cognitive impairment and dementia
WO2019173394A1 (en) 2018-03-05 2019-09-12 Wylder Nation Foundation Compositions and methods for activating signaling through the cb1 cannabinoid receptor for treating and preventing diseases and disorders characterized by abnormal cellular accumulation of sphingolipids such as sphingomyelin
AU2019248216A1 (en) * 2018-04-04 2020-11-12 Eye Co Pty Ltd Low THC hemp extract and method of treatment or prevention of an eye disease
IL271681A (en) 2018-07-18 2020-01-30 Vyripharm Entpr Llc Systems and methods for integrated and comprehensive management of cannabis products
WO2021007659A1 (en) * 2019-07-12 2021-01-21 Canopy Growth Corporation Cannabinoid derivatives
EP4153169A1 (en) * 2020-05-20 2023-03-29 Wylder Nation Foundation Compositions and methods for activating signaling through the cb2 cannabinoid receptor for treating and preventing lysosomal storage diseases and disorders
CN115006404A (en) * 2022-08-09 2022-09-06 昆药集团股份有限公司 Pharmaceutical composition with optic nerve protection effect and application thereof
WO2024172932A1 (en) * 2023-02-13 2024-08-22 Northeastern University Endocannabinoid ligands and related analogs
AU2024337440A1 (en) * 2023-09-09 2026-03-26 Artelo Biosciences Limited Cannabinoid for use in treating eye disorders

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994012466A1 (en) * 1992-11-30 1994-06-09 Yissum Research Development Company Of The Hebrew University Of Jerusalem Fatty acid derivatives and pharmaceutical compositions containing them
WO1996001558A1 (en) * 1994-07-11 1996-01-25 Pate David W Anandamide analogue compositions and method of treating intraocular hypertention using same
WO2001028498A2 (en) * 1999-10-18 2001-04-26 University Of Connecticut Retro-anandamides, high affinity and stability cannabinoid receptor ligands

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7235584B2 (en) * 2000-06-22 2007-06-26 Pharmos Corporation Non-psychotropic cannabinoids
AU2002360436A1 (en) * 2001-11-30 2003-06-17 Osi Pharmaceuticals, Inc. 2-aryl pyrrologpyrimidines for a1 and a3 receptors
US20080064679A1 (en) * 2004-06-24 2008-03-13 Martin Billy R Water Soluble Cannabinoids

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994012466A1 (en) * 1992-11-30 1994-06-09 Yissum Research Development Company Of The Hebrew University Of Jerusalem Fatty acid derivatives and pharmaceutical compositions containing them
WO1996001558A1 (en) * 1994-07-11 1996-01-25 Pate David W Anandamide analogue compositions and method of treating intraocular hypertention using same
WO2001028498A2 (en) * 1999-10-18 2001-04-26 University Of Connecticut Retro-anandamides, high affinity and stability cannabinoid receptor ligands

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CHEN J ET AL: "Finding of endocannabinoids in human eye tissues: Implications for glaucoma", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US LNKD- DOI:10.1016/J.BBRC.2005.03.095, vol. 330, no. 4, 20 May 2005 (2005-05-20), pages 1062 - 1067, XP004844837, ISSN: 0006-291X *
See also references of WO2007130361A1 *
WILEY J L ET AL: "Task specificity of cross-tolerance between DELTA<9>-tetrahydrocanna binol and anandamide analogs in mice", EUROPEAN JOURNAL OF PHARMACOLOGY, ELSEVIER BV, NL LNKD- DOI:10.1016/J.EJPHAR.2005.01.006, vol. 510, no. 1-2, 7 March 2005 (2005-03-07), pages 59 - 68, XP004765702, ISSN: 0014-2999 *

Also Published As

Publication number Publication date
CA2650900A1 (en) 2007-11-15
JP2009538827A (en) 2009-11-12
CN101484004A (en) 2009-07-15
WO2007130361A1 (en) 2007-11-15
AU2007248760A1 (en) 2007-11-15
EP2020850A1 (en) 2009-02-11

Similar Documents

Publication Publication Date Title
EP2038252A4 (en) SUBSTITUTED ACYLANILIDES AND METHODS OF USE THEREOF
EP2054049A4 (en) SUBSTITUTED ACYLANILIDES AND METHODS OF USE THEREOF
EP2081964A4 (en) ALGINATE AND ALGINATE-LYASE COMPOSITIONS AND METHODS OF USE
EP2057465A4 (en) SPECIFIC ORGAN PROTEINS AND METHODS OF USE
EP2066817A4 (en) MOLECULAR SWITCHES AND METHODS OF USE
EP2094085A4 (en) ANTI-CHOLESTEROLMIC COMPOUNDS AND METHODS OF USE
EP2041574A4 (en) CANCER BIOMARKERS AND METHODS OF USE
EP2040541A4 (en) ADJUVANTS AND METHODS OF USE
EP2020850A4 (en) NEW CANNABINOIDS AND METHODS OF USE
EP2167111A4 (en) POLYPEPTIDES AND METHODS OF USE
EP2235034A4 (en) IMMUNOMODULATORY AGENTS AND METHODS OF USE
EP1971266A4 (en) INTRA-UTERINE ULTRASOUNDS AND METHOD OF USE
EP2187742A4 (en) BENZYLBENZENE DERIVATIVES AND METHODS OF USE
EP2019679A4 (en) GLUCOSE TRANSPORT INHIBITORS AND METHODS OF USE
EP2344447A4 (en) GABA CONJUGATES AND METHODS OF USE THEREOF
EP2268673A4 (en) POLYPEPTIDE-POLYMER CONJUGATES AND METHODS OF USE THEREOF
EP2021555A4 (en) STRUCTURAL ELEMENT AND METHODS OF USE THEREOF
EP2101731A4 (en) METHODS AND COMPOSITIONS OF ENDOXIFEN
EP2137168A4 (en) NEW IDO INHIBITORS AND METHODS OF USE
EP2129429A4 (en) ANCHORING APPARATUS AND METHODS OF USE
EP2037821A4 (en) DEVICES AND METHODS OF ATHERECTOMY
EP2340244A4 (en) COMPOUNDS AND METHODS OF USE
EP2012803A4 (en) POLYMER COMPOSITIONS AND METHODS OF PRODUCTION AND USE THEREOF
EP2061476A4 (en) COMPOSITIONS CONTAINING CDP-CHOLINE AND METHODS OF USE THEREOF
EP2084275A4 (en) POLYPEPTIDE LIGANDS TARGETING CARTILAGE AND METHODS OF USE THEREOF

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20081114

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK RS

A4 Supplementary search report drawn up and despatched

Effective date: 20100910

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20110409